Sarepta Therapeutics Inc (SRPT)
123.07
-0.22
(-0.18%)
USD |
NASDAQ |
Nov 04, 16:00
124.11
+1.04
(+0.85%)
After-Hours: 20:00
Sarepta Therapeutics Revenue (Quarterly): 362.93M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 362.93M |
| March 31, 2024 | 413.46M |
| December 31, 2023 | 396.78M |
| September 30, 2023 | 331.82M |
| June 30, 2023 | 261.24M |
| March 31, 2023 | 253.50M |
| December 31, 2022 | 258.43M |
| September 30, 2022 | 230.27M |
| June 30, 2022 | 233.49M |
| March 31, 2022 | 210.83M |
| December 31, 2021 | 201.46M |
| September 30, 2021 | 189.41M |
| June 30, 2021 | 164.09M |
| March 31, 2021 | 146.93M |
| December 31, 2020 | 145.14M |
| September 30, 2020 | 143.92M |
| June 30, 2020 | 137.36M |
| March 31, 2020 | 113.67M |
| December 31, 2019 | 100.11M |
| September 30, 2019 | 99.04M |
| June 30, 2019 | 94.67M |
| March 31, 2019 | 87.01M |
| December 31, 2018 | 84.42M |
| September 30, 2018 | 78.49M |
| June 30, 2018 | 73.53M |
| Date | Value |
|---|---|
| March 31, 2018 | 64.60M |
| December 31, 2017 | 57.28M |
| September 30, 2017 | 45.95M |
| June 30, 2017 | 35.01M |
| March 31, 2017 | 16.34M |
| December 31, 2016 | 5.421M |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | 1.253M |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | 0.027M |
| September 30, 2014 | 1.059M |
| June 30, 2014 | 2.583M |
| March 31, 2014 | 6.088M |
| December 31, 2013 | 2.626M |
| September 30, 2013 | 4.168M |
| June 30, 2013 | 2.951M |
| March 31, 2013 | 4.474M |
| December 31, 2012 | 7.336M |
| September 30, 2012 | 7.574M |
| June 30, 2012 | 11.21M |
| March 31, 2012 | 11.21M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
100.11M
Minimum
Dec 2019
413.46M
Maximum
Mar 2024
226.04M
Average
210.83M
Median
Mar 2022
Revenue (Quarterly) Benchmarks
| Regenxbio Inc | 22.30M |
| Catalyst Pharmaceuticals Inc | 122.71M |
| Vertex Pharmaceuticals Inc | 2.646B |
| Entrada Therapeutics Inc | 94.69M |
| Edgewise Therapeutics Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 6.46M |
| Total Expenses (Quarterly) | 363.63M |
| EPS Diluted (Quarterly) | 0.07 |
| Enterprise Value | 11.52B |
| Gross Profit Margin (Quarterly) | 87.73% |
| Profit Margin (Quarterly) | 1.78% |
| Earnings Yield | 0.60% |
| Operating Earnings Yield | 0.32% |
| Normalized Earnings Yield | 0.9008 |